@article {Travelli829, author = {Cristina Travelli and Valentina Drago and Elena Maldi and Nina Kaludercic and Ubaldina Galli and Renzo Boldorini and Fabio Di Lisa and Gian Cesare Tron and Pier Luigi Canonico and Armando A. Genazzani}, title = {Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells}, volume = {338}, number = {3}, pages = {829--840}, year = {2011}, doi = {10.1124/jpet.111.184630}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {NAD is an essential coenzyme involved in numerous metabolic pathways. Its principal role is in redox reactions, and as such it is not heavily {\textquotedblleft}consumed{\textquotedblright} by cells. Yet a number of signaling pathways that bring about its consumption have recently emerged. This has brought about the hypothesis that the enzymes that lead to its biosynthesis may be targets for anticancer therapy. In particular, inhibition of the enzyme nicotinamide phosphoribosyl transferase has been shown to be an effective treatment in a number of preclinical studies, and two lead molecules [N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide (FK866) and (E)-1-[6-(4-chlorophenoxy)hexyl]-2-cyano-3-(pyridin-4-yl)guanidine (CHS 828)] have now entered preclinical trials. Yet, the full potential of these drugs is still unclear. In the present study we have investigated the role of FK866 in neuroblastoma cell lines. We now confirm that FK866 alone in neuroblastoma cells induces autophagy, and its effects are potentiated by chloroquine and antagonized by 3-methyladenine or by down-regulating autophagy-related protein 7. Autophagy, in this model, seems to be crucial for FK866-induced cell death. On the other hand, a striking potentiation of the effects of cisplatin and etoposide is given by cotreatment of cells with ineffective concentrations of FK866 (1 nM). The effect of etoposide on DNA damage is potentiated by FK866 treatment, whereas the effect of FK866 on cytosolic NAD depletion is potentiated by etoposide. Even more strikingly, cotreatment with etoposide/cisplatin and FK866 unmasks an effect on mitochondrial NAD depletion.}, issn = {0022-3565}, URL = {https://jpet.aspetjournals.org/content/338/3/829}, eprint = {https://jpet.aspetjournals.org/content/338/3/829.full.pdf}, journal = {Journal of Pharmacology and Experimental Therapeutics} }